Max Healthcare Institute
- Market Cap
- ₹1,05,215 Cr
- P/E
- 76.23
Key Fundamentals
MidcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 14.70%
- Debt to Equity
- 0.33
- EPS (TTM)
- ₹14.18
- Book Value
- ₹116.43
- Market Cap
- ₹1,05,215 Cr
- P/E (TTM)
- 76.23
- P/B
- 9.28
- ROE
- 14.70%
- Dividend Yield
- 0.19%
- EBITDA
- ₹2,406 Cr
- 52W High
- ₹1,185.40
- 52W Low
- ₹797.00
- Day Range
- ₹1,050.05 – ₹1,090.00
- Volume
- 95,31,767
Peer Comparison
Healthcare › Healthcare Services › Hospital
| 9,200.00 | 59.00 | 1,32,282 | 12.47 | 0.23% | 21.50% | 17.40% | 27,630 | 2,337 | |
| 1,081.00 | 76.23 | 1,05,215 | 9.28 | 0.20% | 14.70% | 14.70% | 9,146 | 1,380 | |
| 702.20 | 101.77 | 92,366 | 6.01 | 0.00% | 6.72% | 8.30% | 12,370 | 873 | |
| 779.30 | 110.70 | 67,929 | 8.72 | 0.41% | 11.30% | 11.60% | 6,508 | 564 | |
| 825.00 | 59.96 | 62,284 | 5.94 | 0.13% | 11.20% | 13.40% | 9,910 | 1,061 | |
| 1,480.20 | 64.33 | 39,798 | 9.20 | 0.03% | 15.20% | 17.40% | 5,053 | 613 | |
| 1,943.70 | 46.25 | 39,722 | 7.94 | 0.24% | 20.50% | 15.50% | 10,273 | 859 | |
| Median 7 companies | 1,081.00 | 64.33 | 67,929 | 8.72 | 0.20% | 14.70% | 14.70% | 9,910 | 873 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 51
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 29
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 40
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 44
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 20
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 46
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
4- Stock is trading at 9.28 times its book value
- Company has a low return on equity of 13.7% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 13.6% of profits over last 3 years
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 5 | 1 | 13 |
| Oscillators | Strong Bearish | 5 | 1 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Strong Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 79.64
- Bearish
- MACD (12,26,9)
- 36.70
- Bullish
- SMA (50)
- 941.30
- Bullish
- SMA (200)
- 1,010.86
- Bullish
As of
Analyst Rating
20 of 25 analysts rate Buy, 2 Hold, 3 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 5Y | +27.27% |
|---|---|
| 3Y | +22.43% |
| 1Y | +19.14% |
| TTM | +15.17% |
Net profit
| 5Y | Turned to profit |
|---|---|
| 3Y | +9.31% |
| 1Y | +34.01% |
| TTM | +1.69% |
Operating cash flow
| 5Y | +69.13% |
|---|---|
| 3Y | +10.54% |
| 1Y | +13.56% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | +10.56 pp |
|---|---|
| 3Y | −0.41 pp |
| 1Y | +0.48 pp |
| TTM | +0.26 pp |
Revenue by year
| Mar 2017 | ₹1,608 Cr |
|---|---|
| Mar 2018 | ₹1,729 Cr |
| Mar 2019 | ₹1,691 Cr |
| Mar 2020 | ₹1,059 Cr |
| Mar 2021 | ₹2,508 Cr |
| Mar 2022 | ₹3,937 Cr |
| Mar 2023 | ₹4,563 Cr |
| Mar 2024 | ₹5,406 Cr |
| Mar 2025 | ₹7,028 Cr |
| Mar 2026 | ₹8,373 Cr |
Net profit by year
| Mar 2017 | ₹16.00 Cr |
|---|---|
| Mar 2018 | −₹25.00 Cr |
| Mar 2019 | ₹0.00 Cr |
| Mar 2020 | ₹59.00 Cr |
| Mar 2021 | −₹138 Cr |
| Mar 2022 | ₹605 Cr |
| Mar 2023 | ₹1,104 Cr |
| Mar 2024 | ₹1,058 Cr |
| Mar 2025 | ₹1,076 Cr |
| Mar 2026 | ₹1,442 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Max Healthcare Institute Ltd trades at ₹1,040.65 as of 2026-11-19 with a market cap of ₹1,01,288 crore, commanding a PE of 73.39x and a PB of 8.94x. The company has delivered 22% compounded sales growth over three years alongside a modest 13.42% ROE, while maintaining a relatively conservative debt-to-equity ratio of 0.32.
- Strong revenue growth trajectory with compounded sales CAGR of 22% over 3 years and 27% over 5 years, reflecting consistent top-line expansion in the hospital business
- Low leverage with a debt-to-equity ratio of just 0.32, providing financial flexibility for capacity expansion and acquisitions without excessive balance sheet risk
- Healthy long-term stock price CAGR of 24% over 5 years and 20% over 3 years, indicating sustained investor confidence and wealth creation
- Improving return on equity profile — ROE has trended upward from 11% on a 10-year basis to 14% over 5 years and 15% in the last year, suggesting improving capital efficiency
- TTM revenue growth remains solid at 15% compounded sales growth, showing the business continues to scale even on a higher base
- Compounded profit growth of 60% over 5 years demonstrates significant operating leverage and margin expansion over the medium term
- Operating in the Indian private healthcare sector which benefits from structural tailwinds including rising insurance penetration, an aging demographic, and growing per-capita healthcare spend
- Stock trades at 8.94 times book value, a steep premium that prices in substantial future growth and makes the stock vulnerable to de-rating
- TTM profit growth has decelerated sharply to just 1%, a stark contrast to the 5-year compounded profit growth of 60%, raising questions about earnings momentum
- Dividend payout has been low at 13.6% of profits over the last 3 years with a current yield of only 0.20%, offering negligible income return to shareholders
- Three-year average ROE of approximately 13.7% is modest relative to the premium valuation, suggesting the market is pricing in far higher future returns on capital than currently delivered
- The company may be capitalizing interest costs, which could overstate reported profitability by shifting financing expenses from the income statement to the balance sheet
- Stock is down roughly 12% from its 52-week high of ₹1,185.40, and the 1-year stock CAGR of -11% indicates recent negative price momentum
- Three-year compounded profit growth of only 10% against a 22% sales CAGR suggests margin compression or rising costs are absorbing a portion of revenue gains
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Max Healthcare delivered a solid Q2FY27 with 20% revenue growth and healthy EBITDA expansion, while GIC's stake increase to 5% underscores institutional conviction. No material headwinds emerged in the recent news cycle, and pending NCLT proceedings on Kalinga Hospital remain a watch item rather than a near-term risk. The operational and financial trend is firmly positive, with capacity expansion plans likely to sustain growth momentum into H2FY27.
- Q2FY27 revenue up 20% YoY Nov 9
Max Healthcare reported Q2FY27 revenue of ₹3,219 crore (up 20% YoY), operating EBITDA of ₹820 crore (up 18%), and PAT of ₹448 crore (up 10%).
- GIC raises stake to 5% Nov 20
GIC acquired 3,04,579 shares on Nov 18, raising its combined holding in Max Healthcare to 5.005%, signaling institutional confidence.
- Investor forum participation Nov 13
Max Healthcare presented its investor deck covering financials, capacity expansion, and growth strategy at the 29th CITIC CLSA India Forum on Nov 17 and participated in a Goldman Sachs conference on Nov 13.
- Large block trades on NSE Nov 17
Two large trades were flagged on Nov 16-17: ~3.05 lakh shares at ₹1,023.70 (₹31.16 crore) and ~2.41 lakh shares at ₹975.20 (₹23.47 crore). Buyer/seller identities are unknown.
- NCLT Kalinga hearing adjourned Oct 29
The NCLT Cuttack Bench adjourned petitions against subsidiary Kalinga Hospital to Oct 30, 2026, citing lack of time.
- PRSU scheme and CMD pay approved Oct 27
Shareholders approved a new Performance Linked Restricted Stock Unit scheme for 2026 and remuneration for CMD Abhay Soi via postal ballot.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,363 | 1,335 | 1,423 | 1,543 | 1,707 | 1,868 | 1,910 | 2,028 | 2,135 | 2,068 | 2,143 | 2,366 | 2,569 |
| Expenses | 976 | 949 | 1,041 | 1,156 | 1,257 | 1,369 | 1,398 | 1,505 | 1,560 | 1,529 | 1,536 | 1,768 | 1,858 |
| Operating Profit | 387 | 386 | 382 | 387 | 451 | 499 | 512 | 523 | 575 | 538 | 606 | 598 | 711 |
| OPM % | 28% | 29% | 27% | 25% | 26% | 27% | 27% | 26% | 27% | 26% | 28% | 25% | 28% |
| Other Income | 45 | 46 | 45 | 35 | 41 | 33.3 | 47 | 37 | 33 | 45.38 | 48 | 41 | 40.9 |
| Interest | 9 | 11 | 21 | 24 | 34 | 52 | 55 | 55 | 54 | 60 | 67 | 71 | 73.84 |
| Depreciation | 58 | 61 | 70 | 77 | 84 | 98 | 101 | 104 | 108 | 111 | 123 | 132 | 138 |
| Exceptional Items | — | — | — | — | — | −73.63 | — | — | — | −48.24 | — | — | — |
| PBT | 366 | 360 | 336 | 321 | 374 | 309 | 402 | 400 | 446 | 365 | 465 | 436 | 541 |
| Tax % | 24% | 20% | 25% | 26% | 25% | 23% | 21% | 23% | −10% | 17% | 26% | 26% | 23% |
| Net Profit | 277 | 289 | 252 | 236 | 282 | 239 | 319 | 308 | 491 | 301 | 342 | 323 | 414 |
| EPS (₹) | 2.85 | 2.98 | 2.59 | 2.43 | 2.90 | 2.46 | 3.28 | 3.17 | 5.05 | 3.09 | 3.52 | 3.31 | 4.26 |
| YoY Sales growth | 20 | 17 | 17 | 20 | 25 | 40 | 34 | 31 | 25 | 11 | 12 | 17 | 20 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 790 | 912 | 1,608 | 1,729 | 1,691 | 1,059 | 2,508 | 3,937 | 4,563 | 5,406 | 7,028 | 8,373 | 9,146 |
| Expenses | 768 | 890 | 1,467 | 1,616 | 1,535 | 965 | 2,101 | 2,986 | 3,322 | 3,913 | 5,180 | 6,131 | 6,691 |
| Operating Profit | 22 | 22 | 141 | 113 | 156 | 94 | 407 | 951 | 1,241 | 1,493 | 1,849 | 2,243 | 2,455 |
| OPM % | 2.8% | 2.5% | 9% | 7% | 9% | 9% | 16% | 24% | 27% | 28% | 26% | 27% | 27% |
| Other Income | 33 | 35 | 59 | 65 | 56 | 48 | −122 | 110 | 139 | 178 | 156 | 163 | 126 |
| Interest | 43 | 30 | 100 | 99 | 101 | 83 | 179 | 101 | 84 | 60 | 165 | 235 | 271 |
| Depreciation | 49 | 50 | 96 | 94 | 103 | 46 | 174 | 221 | 232 | 245 | 359 | 447 | 504 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | — | −73.63 | −48.24 | — |
| PBT | −38 | −24 | 5 | −15 | 8 | 13 | −69 | 739 | 1,064 | 1,365 | 1,406 | 1,676 | 1,806 |
| Tax % | 0% | 0% | −236% | 65% | 102% | −1% | 67% | 18% | −4% | 23% | 24% | 14% | — |
| Net Profit | −38 | −24 | 16 | −25 | 0 | 59 | −138 | 605 | 1,104 | 1,058 | 1,076 | 1,442 | 1,381 |
| EPS (₹) | −0.78 | −0.44 | 0.29 | −0.47 | −0.06 | 1.10 | −1.42 | 6.24 | 11.37 | 10.88 | 11.07 | 14.82 | 14.18 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 9% | 14% | 14% | 13% | — |
| Sales growth | — | 16 | — | 8 | −2 | −37 | 137 | 57 | 16 | 18 | 30 | 19 | 15 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 489 | 533 | 537 | 537 | 537 | 537 | 966 | 970 | 971 | 972 | 972 | 973 | 973 |
| Reserves | 523 | 762 | 655 | 627 | 426 | 2,016 | 4,673 | 5,313 | 6,439 | 7,436 | 8,409 | 9,774 | 10,359 |
| Borrowings | 296 | 273 | 874 | 981 | 1,003 | 875 | 1,101 | 913 | 689 | 1,299 | 3,010 | 3,478 | 3,795 |
| Other Liabilities | 141 | 171 | 1,080 | 1,157 | 1,389 | 546 | 1,803 | 1,993 | 2,003 | 2,293 | 2,795 | 2,959 | 3,595 |
| Total Liabilities | 1,449 | 1,740 | 3,146 | 3,302 | 3,355 | 3,974 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 | 17,184 | 18,722 |
| Fixed Assets | 430 | 424 | 2,244 | 2,227 | 2,192 | 851 | 6,536 | 7,018 | 7,039 | 8,784 | 11,502 | 12,991 | 13,966 |
| CWIP | 15 | 6 | 46 | 38 | 87 | 28 | 27 | 151 | 252 | 553 | 901 | 593 | 805 |
| Investments | 451 | 840 | 0 | 0 | 1 | 2,182 | 1 | 1 | 1 | 2 | 3 | 5 | 5 |
| Other Assets | 554 | 469 | 856 | 1,036 | 1,075 | 913 | 1,980 | 2,020 | 2,810 | 2,661 | 2,781 | 3,595 | 3,946 |
| Total Assets | 1,449 | 1,740 | 3,146 | 3,302 | 3,355 | 3,974 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 | 17,184 | 18,722 |
Cash Flow
₹ Cr| Particulars | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 39 | 64 | 156 | 166 | 89 | 77 | 118 | 741 | 1,209 | 1,122 | 1,438 | 1,633 |
| Investing | −200 | −330 | −104 | −124 | −17 | −2,641 | 206 | −764 | −1,187 | −1,253 | −1,593 | −1,688 |
| Financing | 176 | 251 | −48 | −48 | −74 | 2,353 | 191 | −294 | −289 | −264 | −163 | 59 |
| Net Cash Flow | 15 | −16 | 4 | −6 | −2 | −210 | 516 | −317 | −266 | −395 | −318 | 4 |
| Free Cash Flow | −15 | 42 | 41 | 100 | −27 | −13 | 1 | 192 | 877 | 342 | 500 | 165 |
| CFO/EBITDA | 223 | 338 | 135 | 166 | 75 | 89 | 15 | 89 | 110 | 93 | 95 | 89 |
Ratios
| Particulars | Mar 2015 (S) | Mar 2016 (S) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 67 | 48 | 53 | 59 | 78 | 33 | 53 | 36 | 27 | 31 | 36 | 42 |
| Inventory Days | 20 | 18 | 20 | 24 | 26 | 43 | 34 | 24 | 30 | 26 | 26 | 23 |
| Days Payable | 171 | 183 | 184 | 227 | 292 | 286 | 274 | 174 | 212 | 207 | 198 | 175 |
| Cash Conversion Cycle | −85 | −117 | −111 | −144 | −188 | −210 | −187 | −114 | −155 | −149 | −136 | −110 |
| Working Capital Days | −15 | −33 | −12 | −24 | −152 | −137 | −44 | −24 | −46 | −43 | −46 | −41 |
| ROCE % | — | 0% | — | 4% | 6% | 4% | 7% | 12% | 15% | 16% | 15% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Max Healthcare Institute insights
70 extracted metrics across FY17–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q2 FY27 concall · Oct 2026PPT
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026PPT
- Concall · May 2026Transcript PPT Recording
- 12 Oct 2026
- 10 Oct 2025
- 4 Apr 2025
- 3 Oct 2024
- 9 Oct 2023
- 13 Nov 2026
- General announcements 4 Nov 2026
- General announcements 3 Nov 2026
Frequently Asked Questions about Max Healthcare Institute
What does Max Healthcare Institute Ltd do?
Where is Max Healthcare Institute Ltd (MAXHEALTH) listed?
Which sector does Max Healthcare Institute Ltd belong to?
What is the market capitalisation of Max Healthcare Institute Ltd?
What is the PE ratio of Max Healthcare Institute Ltd?
What is the 52-week high and low of Max Healthcare Institute Ltd?
Does Max Healthcare Institute Ltd pay dividends?
What is the Return on Equity (ROE) of Max Healthcare Institute Ltd?
Company Information
Max Healthcare Institute Limited is primarily engaged in the providing healthcare services through primary care clinics, multi-speciality hospitals / medical centres and super-speciality hospitals providing operation and management, medical services, clinical, radiology, pathology services and related healthcare services.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MAXHEALTH.md for Max Healthcare Institute Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.